India Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents & Consumables), By Test Location, By Technology, By Platform, By Application, By End Use, And Segment Forecasts, 2025 - 2033

Market Size & Trends

The India molecular diagnostics market size was estimated at USD 1,054.80 million in 2024 and is projected to reach USD 1,717.27 million by 2033, growing at a CAGR of 5.63% from 2025 to 2033. The growth is attributed to an ever-increasing burden of infectious diseases, heightened awareness of early disease detection, and greater access to advanced diagnostic technologies within healthcare settings. PCR-based assays and sample-to-answer platforms are quickly gaining market share due to their accuracy, speed, and usability in decentralized testing sites.

Moreover, the rising incidence of infectious diseases in India is one of the primary factors impacting the India molecular diagnostics industry, particularly for polymerase chain reaction (PCR) testing. Diseases, including tuberculosis (TB), hepatitis, HIV, and vector-borne diseases such as malaria and dengue, continue to be important public health problems. According to the National Tuberculosis Elimination Programme (NTEP), there were approximately 4.4 lakh deaths linked to TB in 2021, which was nearly 29% of TB-related deaths globally. The burden of these diseases necessitates the use of new diagnostic technologies, such as PCR, to ensure accurate detection in a timely manner, allowing patients to receive treatment and enabling control measures to be implemented. In India, roughly 10 million people die every year, and nearly one-fourth of these deaths-over 2.34 million deaths-are due to communicable diseases. Within this group, respiratory infections, specifically influenza and pneumonia, are the leading causes of death and represent the greatest risk to young children and elderly individuals. While respiratory infections have always accounted for the largest share of deaths due to communicable diseases, respiratory infections showed an increase in their impact in the time period of 2020 to 2022 during the COVID-19 pandemic.

The rapid expansion of personalized medicine, oncology, and genetic testing has propelled the growth of the molecular diagnostics market in India. Personalized medicine is a novel approach to medical treatment that considers individual characteristics, such as genetic information, lifestyle, and environment, to develop medicines that are more effective, precise, and targeted to the individual. Promising forces propelling the growth include the advancement of genomic technologies, an increase in the prevalence of chronic and genetic diseases, and rising awareness and demand for personalized medicine. PCR-based products, such as Truenat MTB/RIF, Roche Cobas EGFR Mutation Test, and Qiagen Therascreen KRAS/NRAS PCR kits, are helping clinicians make genomic testing a success, supporting precision treatment plans.

In oncology, the movement toward personalized treatment approaches has transformed cancer management in India. Common cancer therapy typically takes a uniform approach that is not always effective for the patient. Personalized treatment established through genomic profiling allows oncologists to choose therapies that are more likely to be effective based on the genetic profiles of the patient and the tumor. For example, targeted therapies such as Osimertinib for EGFR mutations or trastuzumab for HER2-positive breast cancer utilize specific PCR tests, including Roche Cobas (EGFR) and Qiagen (HER2) PCR kits, to identify suitable candidates. These PCR-based diagnostics enable the rapid and precise identification of mutations, facilitating timely and personalized therapy, which in turn leads to better outcomes and a lower likelihood of side effects in some patients.

Moreover, government initiatives and public-private partnerships (PPPs) have played a crucial role in developing laboratory infrastructure across India. For example, the Pradhan Mantri Jan Arogya Yojana (PMJAY) aims to provide more universal and affordable healthcare services to underprivileged populations, thereby increasing demand for diagnostic services. In partnerships like those in Rajasthan, private companies manage laboratories, install high-quality diagnostic machines, and provide online reporting using Laboratory Information Management Systems (LIMS). This results in more testing capacity, faster turnaround times, and higher accessibility in semi-urban and rural locations. The Ministry of Health and Family Welfare, Government of India highlights the massive scale-up of new TB laboratory capacity: There was an increase of 80% in Designated Microscopy Centers (DMCs) from 13,583 in 2014 to 24,573 in 2023, along with 6,496 new molecular diagnostic laboratories, and 81 Culture and Drug Susceptibility Testing (DST) laboratories by 2023, demonstrating remarkable growth of the molecular diagnostic infrastructure across India.

Additionally, the rise in the presence of private diagnostic chains has significantly contributed to the market's growth. Major players, such as Dr. Lal PathLabs, Metropolis Healthcare, and Thyrocare Technologies, are deliberately expanding their presence in towns classified as Tier 2, Tier 3, and even Tier 4, thereby providing more connection and access to urban as well as rural healthcare in India. Similarly, Co-Diagnostics, Inc. announced the opening of the oligonucleotide synthesis facility of CoSara Diagnostics Pvt. Ltd. in December 2024 in Ranoli, India. As part of the "Make in India" initiative, this facility will produce Co-Dx's patented Co-Primers chemistry used in their laboratory-based PCR tests, as well as at-home and point-of-care PCR testing platforms. Localizing production enables Co-Dx to have better access to India's large and expanding healthcare systems, while also supporting domestic manufacturing and ensuring regulatory compliance.

In conclusion, the molecular diagnostics market in India is rapidly evolving, driven by the push for personalized medicine, the introduction of new oncology therapies, and advancements in genomic technologies. Strong government support, the expansion of private diagnostic networks, and domestic manufacturing through the “Make in India” campaign are improving accessibility and infrastructure. All these factors are establishing an ecosystem positioning India as a destination for precision diagnostics and next-generation healthcare.

India Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the India molecular diagnostics market report based on product, application, technology, test location, platform, and end use:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Reagents and Consumables
• Others
• Test Location Outlook (Revenue, USD Million, 2021 - 2033)
• Point of Care
• Self-Test or OTC
• Central Laboratories
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Polymerase Chain Reaction (PCR)
• Multiplex PCR
• Real-Time PCR
• Open PCR
• Others
• Platform Outlook (Revenue, USD Million, 2021 - 2033)
• Sample-to-answer
• High-throughput Closed Systems
• Open PCR / LDT Platforms
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Gastrointestinal Infections
• Enteric Bacterial
• Salmonella
• Shigella
• Campylobacter
• E. Coli
• Others
• Enteric Viral
• Norovirus
• Rotavirus
• Adenovirus
• Astrovirus
• Sapovirus
• Enteric Parasitic
• Giardia Lamblia
• Cryptosporidium spp.
• Entamoeba Histolytica
• Respiratory Infections
• Viral Respiratory Infections
• Influenza A & B
• SARS-CoV-2
• RSV
• Human Metapneumovirus
• Parainfluenza
• Adenovirus
• Rhinovirus / Enterovirus
• Others
• Bacterial Respiratory Infections
• Mycobacterium Tuberculosis
• Bordetella Pertussis
• Mycoplasma Pneumoniae
• Chlamydophila Pneumoniae
• Others
• Healthcare-Associated Infections
• MRSA
• Clostridium Difficile
• Carbapenemase-Producing Organisms (CPO)
• Others
• Sexually Transmitted Infections & Women’s Health
• HIV
• Neisseria Gonorrhoeae
• Hepatitis B (HBV)
• Hepatitis C (HCV)
• Trichomonas Vaginalis
• Mycoplasma Genitalium
• HSV
• HPV
• Group B Streptococcus (GBS)
• Chlamydia Trachomatis
• Syphilis
• Others
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Others

Please note The report will be delivered in 2-3 business days upon order notification. Show more